menu
Presentation
Patrick Hurban, Ph.D. | March 02, 2020

Immune Landscape Signatures for Tumor Microenvironment Characterization and Therapy Response

Presentation from I-O 360 2020
In this presentation from I-O 360 2020, you will learn:
  • A background on Tumor-Immune activity and the Tumor Microenvironment (TME)
  • The development of Immune Landscape Signatures
  • How to apply Immune Landscape Signatures:
    • The association with key endpoints, response-to-therapy
    • The relationship between Immune Landscape Signatures and Tumor Mutational Burden (TMB)

Related Services:
Immune Landscape Signatures for Characterization of Tumor Microenvironment and Response to Therapy

Gene expression and analysis for detection of 15 Immune Landscape Signatures

Tumor Mutational Burden (TMB) Assay for Response to Immunotherapy

TMB assay utilizing whole exome sequencing (WES) methodology and proprietary variant analysis compendium

A Pan-Cancer Analysis of the TME Shows Reproducibility but Tissue-Dependent Associations between RNA-based Immune Signatures, Tumor Mutational Burden, and Outcomes

Q2 Solutions | EA Genomics Immune Landscape Signatures

Long-Term Disease-Free Survival in High Grade Serous Ovarian Cancer (HGSOC) is Dependent on Immune Microenvironment Characteristics of Primary Tumor

Application of RNA-based immune signatures in predicting disease-free survival

Read More